158 related articles for article (PubMed ID: 37653737)
1. Real-world treatment patterns and survival for locally advanced esophageal squamous cell carcinoma.
Luo HC; Wu JJ; Zhu LJ; Cai LJ; Feng J; Shen ZY; Wu MJ; Chen FF; Fu ZC; Xie FW
Medicine (Baltimore); 2023 Aug; 102(34):e34647. PubMed ID: 37653737
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
3. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
[TBL] [Abstract][Full Text] [Related]
4. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
[TBL] [Abstract][Full Text] [Related]
5. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
Chen J; Yin W; Yao H; Gu W
Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K
JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M
Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600
[TBL] [Abstract][Full Text] [Related]
8. Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence.
Hsieh JC; Chiang PC; Hung TM; Chao YK; Kuo YC; Wen CT; Su PJ; Peng MT; Chen HW; Liu HL; Chang HK; Wu MH; Wang HM
Cancer Med; 2021 Dec; 10(23):8300-8309. PubMed ID: 34706159
[TBL] [Abstract][Full Text] [Related]
9. Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.
Zeng J; Cui X; Cheng L; Chen Y; Du X; Sheng L
Cancer Radiother; 2021 Jul; 25(5):441-446. PubMed ID: 33958272
[TBL] [Abstract][Full Text] [Related]
10. The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma.
Hu L; Kong Z; Meng Q; Wang J; Zhou M; Yu J; Jiang X
Med Sci Monit; 2020 Nov; 26():e927221. PubMed ID: 33243967
[TBL] [Abstract][Full Text] [Related]
11. [The value of the planned neoadjuvant radiotherapy or chemoradiotherapy for the non-radical resection of esophageal squamous cell carcinoma].
Ni WJ; Deng W; Xiao ZF; Zhou ZM; Wang X; Chen DF; Feng QF; Liang J; Lyu JM; Bi N; Deng L; Zhang T; Wang WQ; Xue Q; Gao SG; Mu JW; Mao YS; Wang DL; Zhao J; Gao YS; Huang JF; Tan FW; Zhao L; Lyu F; Zhang GC
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):295-302. PubMed ID: 31014056
[No Abstract] [Full Text] [Related]
12. Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
Abraham P; Gricar J; Zhang Y; Shankaran V
Adv Ther; 2020 Jul; 37(7):3392-3403. PubMed ID: 32533533
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
14. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.
Auclin E; Benitez-Montanez J; Tagliamento M; Parisi F; Gorria T; Garcia-Campelo R; Dempsey N; Pinato DJ; Reyes R; Albarrán-Artahona V; Dall'Olio F; Soldato D; Hendriks L; Nana FA; Tonneau M; Lopez-Castro R; Nadal E; Kazandjian S; Muanza T; Blanc-Durand F; Fabre E; Castro N; Arasanz H; Rochand A; Besse B; Routy B; Mezquita L
Lung Cancer; 2023 Apr; 178():116-122. PubMed ID: 36812760
[TBL] [Abstract][Full Text] [Related]
15. Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis.
Yi Q; Liu C; Cui Y; Yang Y; Li Y; Fan X; Wu K
Cancer Med; 2023 Mar; 12(6):6477-6487. PubMed ID: 37012831
[TBL] [Abstract][Full Text] [Related]
16. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J
JAMA Surg; 2021 Aug; 156(8):721-729. PubMed ID: 34160577
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma.
Shi Z; Zhu X; Ruan C; Wei G; Li J; Qiu H; Gao L; Cai G; Zhangcai Y; Li B; Wang J; Gong Y; Chen J; Zhao W; Wu Y; Ke S; Chen Y
JAMA Netw Open; 2022 Dec; 5(12):e2244619. PubMed ID: 36454568
[TBL] [Abstract][Full Text] [Related]
18. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.
Liu A; Wang Y; Wang X; Zhu L; Nie Y; Li M
Radiat Oncol; 2021 Oct; 16(1):195. PubMed ID: 34600574
[TBL] [Abstract][Full Text] [Related]
19. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.
Li H; Fang Y; Gu D; Du M; Zhang Z; Sun L; Zhou G; Ye J
Radiat Oncol; 2022 Jun; 17(1):105. PubMed ID: 35681233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
